William Blair Has Pessimistic Outlook of AXSM Q1 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Analysts at William Blair lowered their Q1 2025 earnings per share estimates for shares of Axsome Therapeutics in a research report issued to clients and investors on Tuesday, February 18th. William Blair analyst M. Minter now forecasts that the company will post earnings per share of ($1.46) for the quarter, down from their previous estimate of ($0.95). William Blair has a "Outperform" rating on the stock. The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share. William Blair also issued estimates for Axsome Therapeutics' Q2 2025 earnings at ($1.28) EPS, Q3 2025 earnings at ($0.92) EPS, Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($4.23) EPS, Q1 2026 earnings at ($0.39) EPS, Q2 2026 earnings at $0.22 EPS, Q3 2026 earnings at $0.93 EPS, Q4 2026 earnings at $1.62 EPS, FY2026 earnings at $2.38 EPS and FY2027 earnings at $13.85 EPS.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, beating the consensus estimate of ($0.97) by $0.01. The business had revenue of $118.77 million for the quarter, compared to analysts' expectations of $117.83 million. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%.

AXSM has been the subject of a number of other research reports. HC Wainwright upped their price target on Axsome Therapeutics from $190.00 to $200.00 and gave the stock a "buy" rating in a research report on Thursday, February 20th. Truist Financial lifted their price target on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. Bank of America raised their price objective on Axsome Therapeutics from $143.00 to $167.00 and gave the company a "buy" rating in a report on Tuesday, February 11th. Mizuho increased their price target on Axsome Therapeutics from $137.00 to $195.00 and gave the company an "outperform" rating in a research report on Tuesday, February 11th. Finally, Leerink Partners raised their price target on Axsome Therapeutics from $110.00 to $150.00 and gave the company an "outperform" rating in a research note on Monday, February 10th. One equities research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $158.79.

Axsome Therapeutics Stock Down 2.8 %

Shares of Axsome Therapeutics stock traded down $3.63 during trading on Friday, reaching $127.09. The stock had a trading volume of 1,231,648 shares, compared to its average volume of 1,107,279. The company has a current ratio of 2.11, a quick ratio of 2.04 and a debt-to-equity ratio of 3.22. The company has a market capitalization of $6.20 billion, a price-to-earnings ratio of -21.22 and a beta of 1.05. The stock has a fifty day moving average price of $102.11 and a two-hundred day moving average price of $95.31. Axsome Therapeutics has a 52 week low of $64.11 and a 52 week high of $139.13.

Insider Activity at Axsome Therapeutics

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the completion of the sale, the chief financial officer now directly owns 42,187 shares in the company, valued at $5,529,450.09. This trade represents a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 22.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Axsome Therapeutics

A number of large investors have recently made changes to their positions in AXSM. BVF Inc. IL boosted its stake in Axsome Therapeutics by 32.7% in the 4th quarter. BVF Inc. IL now owns 1,388,064 shares of the company's stock valued at $117,444,000 after purchasing an additional 342,064 shares during the period. FMR LLC boosted its position in shares of Axsome Therapeutics by 20.6% in the third quarter. FMR LLC now owns 1,088,087 shares of the company's stock valued at $97,786,000 after acquiring an additional 185,951 shares during the period. Geode Capital Management LLC grew its stake in shares of Axsome Therapeutics by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 912,538 shares of the company's stock valued at $77,228,000 after acquiring an additional 4,079 shares in the last quarter. Wellington Management Group LLP increased its position in Axsome Therapeutics by 1.1% during the third quarter. Wellington Management Group LLP now owns 742,745 shares of the company's stock worth $66,750,000 after acquiring an additional 8,125 shares during the period. Finally, Invesco Ltd. increased its position in Axsome Therapeutics by 10.8% during the fourth quarter. Invesco Ltd. now owns 692,464 shares of the company's stock worth $58,589,000 after acquiring an additional 67,285 shares during the period. Institutional investors own 81.49% of the company's stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.